🔥World Cholangiocarcinoma (CCA) Day 2024🔥 #WorldCCADay 💪The multidisciplinary TEAM in Toronto 🇨🇦 is growing😅 👉Dedicated to fight this devastating disease 🙏to all who support! #BeClearOnCCA ESMO - Eur. Oncology EASL Education ILCA @curecca #livertwitter University Health Network UHN Research Princess Margaret Cancer Centre Research

🎉 Welcome to the team Robert Grant! Dr. Grant's research focuses on using machine and deep learning to integrate multimodal data to improve clinical decision-making for people with cancer ices.on.ca/ices-scientist…

A prognostic #MachineLearning system can promote early palliative care. ➡️ brnw.ch/21wHciH #PallOnc Machine Learning 4 Oncology

🔥Great summary by Kevin He of his study! 👏👏

REACT is an AI chatbot to help healthcare workers triage care for patients with cancer. Looking forward to Robert Grant Princess Margaret Cancer Centre UHN Research pitching his innovation at Falcons' Fortunes this Thursday. #FF2024 facit.ca/falcons-fortun…

🌞Great sunny day in Toronto, just starting the Cholangiocarcinoma in PSC Symposium at University Health Network 🤩Looking forward to great talks and discussion on new strategies for prevention and treatment of cancer in PSC ESMO - Eur. Oncology EASL Education ILCA Cholangiocarcinoma Foundation #livertwitter @sapisochin

PASS-01 trial #PDAC #ASCO24 ➡️rand ph2 mFFX vs.GnP ➡️WGS/RNA/PDO/CTCs/ctDNA ✅PP PFS 5.5 (GnP) vs. 4.0mths (mFFX) ➡️PP ❌gBRCA/PALB2 >KRASWT in GnP ➡️MTB directed 2nd line ➡️ GnP remains a backbone for drug dvp ➡️basal-like unmet need Proud Dr. Amber Habowski as translational leads

Great summary of our recent study on the performance of LLMs on medical oncology exams in JAMA Network Open. Amazing effort from Ian Hirsch and the team! Thanks to The Princess Margaret Cancer Foundation Princess Margaret Cancer Centre Cancer Digital Intelligence Ontario Institute for Cancer Research (OICR) ICES

Thank you to TD Ready Commitment. We are honoured and appreciate the responsibility that comes with this incredible gift. Our team is already hard at work to realize our vision of using AI to improve cancer care.

Congrats to David, Kevin (co-supervised with Benjamin Haibe-Kains), and Yuanchang (with PanCuRx at @oicr_news and Notta Lab) ! And huge thank you to MOHCCN for the support!

The The PRECEDE Consortium Study, the nation’s largest pancreatic cancer early detection initiative, is holding its annual meeting in San Diego on Nov 7-8. We aim to improve early detection and increase the 5-year survival rate to 50% in the next decade! bit.ly/3ApP5Lp

Inspiring to see the international community come together at the PRECEDE Annual Meeting to figure out how to prevent pancreatic cancer! Our screening program at Princess Margaret Cancer Centre contributes to this important initiative

Congrats to PhD student Noke's team for winning the Temerty Centre for AI in Medicine (T-CAIREM) Health Datathon! mailchi.mp/utoronto/tcair…

Final COMPASS trial data advanced #PDAC ➡️268 WGS& 253RNA-seq ➡️basal-like& hi GRIm-S ⬇️OS, both unique TME inc CD8 variation,NB primaries vs mets ➡️LTS :HRD, KRAS WT ➡️KRAS major enriches basal, >type II DM ➡️LAPC≠intact SMAD4 ➡️47% receive 2nd line tx nature.com/articles/s4146…

Sharing our research in JAMA Oncology predicting chronic kidney disease after cisplatin treatment. Thanks to Kevin He, Abhijat Kitchlu | Onconephrology, Marzyeh, and the rest of the team, as well as ICES, Princess Margaret Cancer Centre Research, The Princess Margaret Cancer Foundation, and Ontario Institute for Cancer Research (OICR) for their support jamanetwork.com/journals/jamao…

Study demonstrated cisplatin treatment was followed by a predictable decrease in the estimated glomerular filtration rate (eGFR), placing patients with a lower baseline eGFR at the highest risk of CKD. ja.ma/41eBxMU

Terrific preprint by Hartland Jackson using imaging mass cytometry (IMC) & matched genomics for building multimodality prediction models: Integrated spatial proteomics of human PDAC uncovers an expanded tumour–immune– stroma spectrum with genomic associations biorxiv.org/content/10.110…

PASS-01:ph II mFFX v GnP;#PDAC denovo met ds; excl gBRCA/PALB2 ➡️no clinically sig diff GnP v mFFX ➡️basal-like poor OS-mPFS on mFFX 3 mths ➡️54% receive 2nd line; mOS<6mths ➡️PDOs/ctDNA to come Dr. Amber Habowski 1st-line biomarkers essential-RAS &🤞subtype doi.org/10.1200/JCO-25…

New research out today: ML can predict future symptoms during cancer treatment from EHR data. Congrats to Noke for his first paper during his PhD.👏 Great to collaborate with Cancer Digital Intelligence and the rest of the team. JCO Clinical Cancer Informatics Princess Margaret Cancer Centre Research. ascopubs.org/doi/10.1200/CC…